Keywords
Coronary heart diseases
Hypercholesterolemia
Lactobacilli
Probiotics
Lactose intolerance
Hypertension
How to Cite
Abstract
Present day lifestyle accompanied by numerous occupational health hazards; make us susceptible to a near infinite list of health issues. Probiotics have been in use for a long time. These confer the host with health benefits. The human intestine hosts a number of organisms. These organisms influence overall health in many ways, which can be both degrading or improvising. Lactobacilli are the natural inhabitants of the gut and hence the most favorable probiotic organisms. Recent studies have emphasized on the use of probiotics as a complementary therapy against hypercholesterolemia. Hypercholesterolemia ranks high as a major health concern. More rampant among the aged peers, this metabolic derangement is the chief cause of coronary heart diseases. Prolonged elevated levels of serum cholesterol can lead to atherosclerosis. Treatments in the current time frame include statins and other chemotherapeutic agents, which help delaying, but fail to ward off the inevitable. Probiotic treatments, with negligible or rather no adverse side effects are gaining ground. Several lactic acid bacteria have been subjected to scientific scrutiny and their utility in treating this menace has been proven. Besides hypercholesterolemia, probiotics aid in alleviating lactose intolerance, hypertension and allergies, promote general intestinal health and alleviate gastrointestinal disorders and have also been found effective in certain cases of cancer. This review is dedicated to throw lighton the various health benefits associated with the use of probiotics
References
Aattouri N, bouras M, Tome D, Marcos A, Lemonnier D. 2002. “Oral ingestion of lactic acid bacteria by rats increases lymphocytic proliferation and interferon γ production”, Br J Nutr., 87:367-373.
Allen SJ, Okoko B, Marinez E, Gregorio G and Dans LF. 2003. “probiotics for treating infectious diarrhea”, Cochrane Database of Systematic Reviews 2, CD003048.
Anderson JW and Gilliland SE. 1999. Effect of Fermented Milk (Yogurt) Containing Lactobacillus acidophilus L1 on Serum Cholesterol in Hypercholesterolemic Humans. Journal of the American College of Nutrition 18(1):43-50.
Barun K. 2009. Bhattacharyya, “Emergence of Probiotics in Therapeutic Applications”, International Journal of Pharmaceutical Sciences and Nanotechnology 2(1):383-389.
Bukowska D, Zguczynski L, MierzejewskaKrzyzowska B. 2002. Axonal collateral branching of neurones in the inferior olive projecting to the cerebellar paramedian lobule in the rabbit. Cells Tissues Organs. 172:37-47.
Casas IA and Dobrogosz WJ. 2000. “Validation of the probiotic concept: Lactobacillus reuteri. Lactobacillus reuteri confers broad spectrum protection against diseases in humans ans animals”, MicrobEcol Health Dis., 12:247-285.
David Collins M, Glen R Gibson. 1999. “Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut”, Am J ClinNutr, 69(suppl): 1052S-1057S.
De Rodas BZ, Gilliland SE and Maxwell CV. 1996. Hypercholesterolemic action of Lactobacillus acidophilus ATCC 43121 and calcium in swine with hypercholesterolemia induced by diet. J. Dairy Sci., 79:2121-2128.
De Santis A, Famularo G and De Simone C. 2000. “Probiotics for the hemodynamic alterations of patients with liver cirrhosis”, Am J Gastroentrol., 95:323-324.
Dodd HM, Gasson MJ. Bacteriocins of lactic acid bacteria. In Gasson M.J., de Vos, W.M. Ed. Genetics and biotechnology of lactic acid bacteria, Glasgow, United Kingdom: Blackie Academic and Professional 211-251.
FAO/WHO. 2001. “Health and Nutritional Properties of Probiotics in Food including powder Milk with Live Lactic Acid Bacteria”, Report of a joint FAO/WHO expert consultation on evaluation of health and, nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, http://www.who.int/foodsafety/publications/fs_management/probiotics/en/index.html.
FAO/WHO. 2002. Drafting Guidelines for the evaluation of probiotics in foods. Report of a joint FAO/WHO Working Group, London Ontario, Canada, April 30 and May 1, 2002. Retrieved April 30 and May 1 2000, from http://www.who.int/foodsafet y/fs_management/en/probiotic_guidelines.pdf
Frias J. 2008. Young Soo Song, Cristina MartinezVillaluenga, Elvira Gonzalez De Mejia and Concepcion VidalValverde, J Agric Food Chem., 56(1):99-105.
Friend BA and Sahani KM. 1984. “Antitumor properties of Lactobacilli and dairy products fermented by lactobacilli”, J Food Prot., 47:717-723.
Fuller R. 1989. “A Review: probiotics in man and animals”, J Appl Bacteriol., 66:365-378.
Gill HS and Guarner F. 2004. Probiotics and human health: a clinical perspective. Postgrad Med J., 80:516-526.
Gilliland SE and Walker DK. 1990. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce hypocholesterolemic effect in humans. J. Dairy Sci., 73:905-911.
Gilliland SE, Nelson CR and Maxwell C. 1985. Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol., 49:377-381.
Gilliland SE. 1990. Health and Nutritional Benefits from lactic acid bacteria. FEMS Microbiol Rev., 87:175-188.
Goldin BR and Gorbach SL. 1992. “Probiotics for humans”, in Probiotics, Scientific Basis (Ed: Fuller R.), Chapman and Hall, London. 355-376.
Goldin BR, Gualteriand L, Moore RP. 1996. The effect of Lactobacillus GG on the initiation and promotion of dimethylhydrazine-induced intestinal tumors in the rat. Nutr Cancer., 25:197-204.
Goltz V, Romankiewiez JA, Moss J and Murr HV. 1974. “Prophylaxis against ampicillin associated diarrhea with Lacrobacilluspreparation”, Am J Hosp Pharm., 36:754.
Gorbach SL. 2000. Probiotics and gastrointestinal health. Am J Gastroentrol., 95: S2-S4.
Guarner F, Schaafsma GJ. 1998. Probiotics. International Journal of Food Microbiology 39:237-238.
Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y and Takano T. 1996. A placebo controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J ClinNutr., 64:767-771.
Hatakka K, Maitio J, korpela M. 2003. “Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis: a pilot study”, Scand J Rheumatoid 32:211-215.
Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, Wolner-Hanssen P. and Holmes KK. 1996. “Hydrogen peroxide producing lactobacilli and acquisition of vaginal infections”, J Infect Dis., 174:1058 -1063.
HodaMahrous. 2011. “Probiotics bacteria from Egyptian in fants cause cholesterol removal in media and survive in yoghurt”, Food and Nutrition Sciences 2:150-155.
Holzer M, Mayrhuber E, Danner H and Braun H. 2003. “The role of Lactobacillus buchneriin forge preservation”, Trends Biotechnol., 21(6):282-286.
Hosono A. 1986. “Anti-mutagenic properties of lacticacid-cultured milk on chemical and fecal mutagens”, j Dairy Sci., 69:2237-2242.
Hosono A, Tono-Oka T. 1995. “Binding of cholesterol with lactic acid bacterial cells”, Milchwissenschaft. 50:556-560.
Jiang T, Mustapha A, Savaiano DA. 1996. Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum.J. Dairy Sci., 79(5):750-757.
Kailasapathy K, Chin J. 2000. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol. Cell Biol., 78:80-88.
Karthick Raja Namasivayam S, Sivasubramanian S and Prakash P. 2011. Evaluation of changes in proximate composition of Bacteriocin supplemented Prawn. Journal of research in Biology 1: 6-14.
Kim GB, Miyamoto CM, Meighen EA, Lee BH. 2004. Cloning and characterization of the bile salt hydrolase genes (bsh) from Bifidobacterium bifidium strains. Appl. Environ. Microbiol., 70:5603–5612.
Langhendries JP, Detry J, Van Hees J, Lamboray JM, Darimont J, Mozine MJ, Secretin MC and Senterre J. 1995. Effect of a fermented infant formular containing viable Bifidobacteria on the faecal flora composition and pH of healthy full-term infants. J. Pediatric Gastroenterol. Nutr., 21:177-181.
Lin SY and Chen CT. 2000. “Reduction of cholesterol by Lactobacillus acidophilus in culture broth” J Food Drug Anal., 8:97-102.
Lutgens E. 2004. Daemen, “HMG-CoA reductase inhibitors: lipidlowering and beyond”, Drugs Discovery Today: Therapeutic Strategies 1:189-194.
Mack DR, Michail S, Wei S, McDougall L and MA. 1999. Hollingsworth, “Probiot ics inhibit enteropathogenicE. coli adherence in vitro by inducing intestinal mucin gene expression, Am J Physiol., 276: G941-G950.
Mallen A, Jarstrand C and Pahlson C. 1992. “Treatment of bacterial vaginosis with lactobacilli”, Sex trans Dis., 19:146-148.
Mandel DR, Eichas K and Holmes J. 2010. “Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial”, BMC Complement Altern Med., 10:1-1.
Mann GV, Spoerry A. 1974. “Studies of a surfactant and cholesteremia in the Maasai”, Am J Clin. Nutr., 27:464-469.
Marrteau P, Flourie B, Vhastang C, desjeux JF and Rambaud JC. 1990. Effect of the microbial lactase (EC 3.2.1.23) activity in yoghurt on the intestinal absorption of lactose: an in vivo study in lactase-deficient humans. Br J Nutr., 64:71-79.
Mary Ellen Sanders. 2000. Symposium: Probiotic Bacteria: Implications for Human Health, “Considerations for use of probiotic bacteria to modulate human health”, J Nutr., 130:384S-390S.
McIntosh GH, Royle PJ and Playne MJ. 1999. “A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats”, Nutr Cancer 35:153-159.
McNamara DJ, Lowell AM and Sabb JE. 1989. “Effect of yogurt intake on plasma lipid and lipoprotein levels in normolipidemic males”, Atherosclerosis 79:167 -171.
Meei-Yn Lin and Tseng-Wei Chen. 2000. “Reduction of Cholesterol by Lactobacillus acidophilus in Culture Broth”, Journal of Food and Drug Analysis 8(2):97-102.
Nakamura Y, Masuda O and Takano T. 1996. Decrease of tissue angiotensin-1-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci. Biotechnol. Biochem., 60:488- 489.
Nakamura Y, Yamamoto N, Sakai K and Takano T. 1995. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin-1- converting enzyme. J. Dairy Sci., 78:1253-1257.
Nguygen TDT, Kang JH and Lee MS. 2007. “Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol lowering effects, International Journal of Food Microbiology 113(3):358-361.
Noh DO, Kim SH, Gilliland SE. 1997. “Incorporation of cholesterol into the cellular membrane of Lactobacillus acidophilus ATCC 43121, J Dairy Sci., 80:3107-3113.
Ouwehand AC, Salminen S and Isolauri E. 2002. “Probiotics an overview: an overview of beneficial effects”, Antoine van Leeuwenhoek 82:279-289.
Parvez S, Malik KA, Ah Kang S and Kim HY. 2006. “Probiotics and their fermented food products are beneficial for health”, J ApplMicrobiol., 100:1171-1185.
Perdigon G, De Jorrat MEB, de Petrino SF and Valverde de Budegeur M. 1991. “Effect of oral administration of Lactobacillus casei on various biological functions of the host”, Food AgricImmunol., 3:93-102.
Pulusani SR and Rao DR. 1983. “Whole body liver, and plasma cholesterol levels in rats fed Thermophilus, Bulgaricus and Acidophilus milks, J food Sci., 48:2880281.
Ratna Sudha M, Prashant Chauhan, Kalpana Dixit, Sekhar Babu, Kaiser Jamil. 2009. Probiotics as complementary therapy for hypercholesterolemia. Biology and Medicine 1(4):1-13.
Reddy BS and Rivenson A. 1993. “inhibitory effect of Bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amino,3-methylimidazo [4,5-f]quinolone, a food mutagen”, Cancer Res., 1:3914- 3918.
Rolfe RD. 2000. “The role of probiotic cultures in the control of gastrointestinal health”, J Nutr, 130(2S):396S402S.
Rowland I. 2004. “Probiotics and colorectal cancer risk”, Br J utr., 91:805-807.
Saavedra J. 2000. Probiotics and infectious diarrhea. Am J Gastroenterol., 95: S16-S18.
Sanders ME and Klaenhammer TR. 2001. Invited Review: The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy sci., 84:319-331.
Sandine WE. 1979. “Role of lactobacillus in the intestinal tract”, J Food Protect., 42:259-262.
Sawada H, Furushiro M, Hirai K, Motoike M, Watanabe T and Yokokura. 1990. “Purification and characterization of an antihypertensive compound from Lactobacillus casei, Agric Biol Chem., 54:3211-3219.
Schultz M and Sartor RB. 2000. Probiotics and inflammatory bowel diseases. Am J Gastroenterol., 95:19S-21S.
Sharper AG, Jones KW, Kyobe J. 1963. “Serum lipids in the three nomadic tribes of Northern Kenya, Am j Clin Nutrit., 13:135-146.
Spiegel CA. 1991. “Bacterial vaginosis”, ClinMicrobiol Rev., 4:485-502.
Stanton C, Gardiner G, Meehan H, Collins K, Fitzgerald G, Lynch PB, Ross RP. 2001. “Market potential for probiotics”, 2001, Am J Clin Nutr, 73(suppl):476S-483S.
Suvarna VC, Boby VU. 2005. “Probiotics in human health: A current assessment”, CURRENT SCIENCE, 88:11.
Takano T. 1998. “Milk derived peptides and hypertension reduction”, Int Dairy J., 8:375-381.
Walker AW, Duffy LC. 1998. Diet and bacterial colonization: Role of probiotics and prebiotics: Review. J. Nutr. Biochem., 9:668-675.
Ziarno M, Sekul E, LafrayaAguado A. 2007. “Cholesterol assimilation by commercial yoghurt starter cultures” Acta Sci Pol Technol Aliment 6(1):83-94.
Copyright license for the research articles published in Journal of Research in Biology are as per the license given below
Creative Commons License
Journal of Research in Ecology is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0). (www.creativecommons.org)
Based on a work at www.jresearchbiology.com
What this License explains us?
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms.
[As given in the www.creativecommons.org website]
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.